234 related articles for article (PubMed ID: 24931061)
1. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
Sourbeer KN; Howard LE; Andriole GL; Moreira DM; Castro-Santamaria R; Freedland SJ; Vidal AC
BJU Int; 2015 May; 115(5):736-43. PubMed ID: 24931061
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
3. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
4. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.
Freedland SJ; Hamilton RJ; Gerber L; Banez LL; Moreira DM; Andriole GL; Rittmaster RS
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):254-9. PubMed ID: 23567655
[TBL] [Abstract][Full Text] [Related]
5. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
6. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
[TBL] [Abstract][Full Text] [Related]
7. Effect of dutasteride on the risk of prostate cancer.
Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
[TBL] [Abstract][Full Text] [Related]
8. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
Fowke JH; Howard L; Andriole GL; Freedland SJ
Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
Sciarra A; Maggi M; Fasulo A; Salciccia S; Gentile V; Cattarino S; Gentilucci A
Urologia; 2017 Aug; 84(3):158-164. PubMed ID: 28430341
[TBL] [Abstract][Full Text] [Related]
10. Decision analysis of dutasteride use for patients with negative prostate biopsy.
Vickers AJ; Sjoberg DD
Urology; 2015 Feb; 85(2):337-41. PubMed ID: 25623680
[TBL] [Abstract][Full Text] [Related]
11. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).
Schröder F; Bangma C; Angulo JC; Alcaraz A; Colombel M; McNicholas T; Tammela TL; Nandy I; Castro R
Eur Urol; 2013 May; 63(5):779-87. PubMed ID: 23176897
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
van Leeuwen PJ; Kölble K; Huland H; Hambrock T; Barentsz J; Schröder FH
Eur Urol; 2011 Feb; 59(2):183-90. PubMed ID: 21130560
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.
Perrotti M; Jain R; Abriel LM; Baroni TE; Corbett AB; Tenenbaum SA
Urol Oncol; 2012; 30(2):133-8. PubMed ID: 20800512
[TBL] [Abstract][Full Text] [Related]
14. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.
Vidal AC; Howard LE; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
Clin Cancer Res; 2015 Feb; 21(4):756-62. PubMed ID: 25520389
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
[TBL] [Abstract][Full Text] [Related]
16. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
17. The metabolic syndrome is associated with more aggressive prostate cancer.
Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.
Schwarzman LS; Pagani RL; Ohlander SJ; Mima M; Abern MR; Andriole GL; Freedland SJ; Moreira DM
Urology; 2020 Mar; 137():97-101. PubMed ID: 31733275
[TBL] [Abstract][Full Text] [Related]
19. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
Fleshner NE; Lucia MS; Egerdie B; Aaron L; Eure G; Nandy I; Black L; Rittmaster RS
Lancet; 2012 Mar; 379(9821):1103-11. PubMed ID: 22277570
[TBL] [Abstract][Full Text] [Related]
20. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
